Boston Scientific (BSX) is down about 3% as investors continue to reprice the stock following this week’s earnings update, where the company cut its full-year 2026 profit forecast and trimmed its revenue growth view even though it reported a first-quarter beat. The market reaction is centered on the outlook reset and management’s description of “unanticipated headwinds,” which shifts the narrative from near-term execution to forward growth durability. (investing.com)

The outlook reduction reflects pressures in several prominent franchises, with commentary pointing to challenges in electrophysiology (including pulsed-field ablation competition/share dynamics) and the Watchman business. Management noted Watchman volume declines beginning in February—an important sentiment hit because Watchman has been a marquee growth driver—while the electrophysiology business is facing intensifying competition even as the category grows. (medtechdive.com)

Following the outlook reset, analysts have been adjusting models and price targets, reinforcing the idea that the near-term debate is less about Q1 results and more about 2026 trajectory. Truist lowered its price target while keeping a Buy rating, and other firms also reduced targets after the quarter, signaling a broad recalibration of expectations rather than an isolated downgrade event. (investing.com)

With the stock trading lower today, investors are focused on whether Boston Scientific can stabilize trends in Watchman and defend positioning in electrophysiology while maintaining the company’s stated growth and margin priorities. Near-term catalysts are likely to be incremental datapoints on procedure volumes, competitive share signals in EP, and any further updates to 2026 guidance assumptions as the year progresses. (medtechdive.com)